SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Year: 2025
Type: review
Abstract: Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual risk remains. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management. Beyond glycemic control, these agents provide distinct and complementary cardiorenal benefits through mechanisms such as hemodynamic modulation, anti-inflammatory effects, and metabolic adaptations. Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes. SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. Although indirect comparisons suggest that SGLT2 inhibitors may offer greater protection against kidney function decline, direct head-to-head trials are lacking. Combination therapy holds promise, however further studies are needed to define optimal treatment strategies. This review synthesizes current evidence, evaluates comparative effectiveness, and outlines future directions in DKD management, emphasizing precision medicine approaches to enhance clinical outcomes. The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure.
Source: Diabetes & Metabolism Journal
Author: Jae Hyun Bae
Institutions: Seoul National University, Seoul National University Hospital
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Keywords: diabetic nephropathy, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, albuminuria, glomerular hyperfiltration, heart failure, atherosclerotic cardiovascular events, combination therapy, precision medicine, CREDENCE trial, DAPA-CKD trial, EMPA-KIDNEY trial, FLOW trial, renin-angiotensin-aldosterone system inhibitors
Open Access status: gold
Estimated APC paid: $500
OpenAlex ID: W4410016396
